Co se změnilo v léčbě nemocných s dyslipidemií?

Title in English What has changed in treatment of patients with dyslipidemia?

KYSELÁK Ondřej SOŠKA Vladimír

Year of publication 2017
Type Article in Periodical
Magazine / Source Interní medicína pro praxi
MU Faculty or unit

Faculty of Medicine

Field Biochemistry
Keywords cardiovascular diseases; ESC/EAS guidelines 2016; LDL cholesterol; statins; ezetimibe; PCSK9 inhibitors
Description Dyslipidemia is very frequent metabolic disease in general population of developed countries. Last year, the European Society of Cardiology (ESC) and European Society of Atherosclerosis (EAS) released new guidelines for management of dyslipi-daemias. In some groups of patients, the criteria for estimation of individual cardiovascular risk were changed. Recommendations for target LDL cholesterol values were also modified and this is why reaching the target level of LDL cholesterol should be now more difficult Therefore, combination of hypolipidemic drugs and using new drugs (as PCSK9 inhibitors) will be needed. Patient's compliance to long-term treatment can be improved also by a new fixed combination of hypolipidemic drugs ("polypills").

You are running an old browser version. We recommend updating your browser to its latest version.

More info